Kyntra Bio, Inc. KYNB
3.82 USD +0.25 (+7.00%)
Nov 11, 2026, 2:38 PM EST
3.60 Day range 3.82
3.50 52-week range 10.47
- YTD
- -56.49%
- 1 year
- -61.57%
- Market cap
- 15.47M
- EPS (ttm)
- -7.64
- YTD return
- -56.49%
- 1-year return
- -61.57%
- Volume
- 17.54K
- Avg volume
- 24.42K
- Open
- 3.61
- Previous close
- 3.57
- Day's range
- 3.60 – 3.82
- 52-week range
- 3.50 – 10.47
5D -1.30 (-26.69%)
Financials — quick view
KYNB Revenue — quarterly -1.47M
KYNB Net income — quarterly 11.97M
KYNB EPS — quarterly 2.96
News
Kyntra Bio Inc (NASDAQ:KYNB) Stock Has Average Price Target of $36.80 According to Analysts - Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41 
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target - Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan
UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimate 
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript 
This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35
Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia Patients
Your note
Sign in to keep a note on KYNB — it syncs with the Stock Master app.